[미국특허]
Cancer stem cell antigen vaccines and methods
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/00
C12N-005/095
출원번호
US-0365666
(2012-02-03)
등록번호
US-9023338
(2015-05-05)
발명자
/ 주소
Yu, John S.
출원인 / 주소
Cedars-Sinai Medical Center
대리인 / 주소
Fish & Richardson P.C.
인용정보
피인용 횟수 :
2인용 특허 :
46
초록
Method of stimulating an immune response (e.g., to treat cancer) include administering to a patient a composition including dendritic cells that present cancer stem cell antigens. Compositions including cancer stem cell antigens are also provided herein.
대표청구항▼
1. A method of treating a glioma in a patient, the method comprising: obtaining a population of dendritic cells;contacting the dendritic cells with one or more isolated peptides of CD133 under conditions such that the dendritic cells present the one or more isolated peptides of CD133, wherein the on
1. A method of treating a glioma in a patient, the method comprising: obtaining a population of dendritic cells;contacting the dendritic cells with one or more isolated peptides of CD133 under conditions such that the dendritic cells present the one or more isolated peptides of CD133, wherein the one or more isolated peptides of CD133 are peptides of 8 to 10 contiguous amino acid residues of amino acid residues 325-350 of SEQ ID NO: 53; andadministering to the patient a composition comprising the dendritic cells. 2. The method of claim 1, wherein the dendritic cells are autologous. 3. The method of claim 1, wherein the dendritic cells are allogeneic. 4. The method of claim 1, wherein the one or more isolated peptides of CD133 are synthetic. 5. The method of claim 1, wherein the patient is human. 6. The method of claim 5, wherein the patient's tumor is resistant to treatment with a chemotherapeutic agent. 7. The method of claim 5, wherein the patient's tumor has recurred following resection. 8. The method of claim 5, wherein the patient is concurrently receiving, or has received, at least one of chemotherapy, radiation therapy, and surgical therapy. 9. The method of claim 1, further comprising measuring the cytotoxic T cell response to the glioma tumor cells after the administration of the dendritic cells. 10. A method of treating a glioma in a patient, the method comprising: administering to the patient a composition of dendritic cells that present CD133 peptides, wherein the CD133 peptides are peptides of 8 to 10 contiguous amino acid residues of amino acid residues 325-350of SEQ ID NO:53. 11. The method of claim 10, wherein the patient is human. 12. The method of claim 11, wherein the patient's tumor is resistant to treatment with a chemotherapeutic agent. 13. The method of claim 11, wherein the patient's tumor has recurred following resection. 14. The method of claim 11, wherein the patient is concurrently receiving, or has received, at least one of chemotherapy, radiation therapy, and surgical therapy. 15. The method of claim 10, wherein the dendritic cells are allogeneic. 16. A method of treating a glioma in a patient, the method comprising: obtaining a population of dendritic cells;contacting the dendritic cells with one or more isolated peptides of CD133 under conditions such that the dendritic cells present the one or more isolated peptides of CD133, wherein the one or more isolated peptides of CD133 are peptides of 13 to 20 contiguous amino acid residues of amino acid residues 325-350 of SEQ ID NO:53; andadministering to the patient a composition comprising the dendritic cells. 17. The method of claim 16, wherein the dendritic cells are autologous. 18. The method of claim 16, wherein the one or more isolated peptides of CD133 are synthetic. 19. The method of claim 16, wherein the patient is human. 20. The method of claim 19, wherein the patient's tumor is resistant to treatment with a chemotherapeutic agent. 21. The method of claim 19, wherein the patient's tumor has recurred following resection. 22. The method of claim 19, wherein the patient is concurrently receiving, or has received, at least one of chemotherapy, radiation therapy, and surgical therapy. 23. The method of claim 16, further comprising measuring the cytotoxic T cell response to the glioma tumor cells after the administration of the dendritic cells. 24. The method of claim 16, wherein the dendritic cells are allogeneic. 25. A method of treating a glioma in a patient, the method comprising: administering to the patient a composition of dendritic cells that present CD133 peptides, wherein the CD133 peptides are peptides of 13 to 20 contiguous amino acid residues of amino acid residues 325-350 of SEQ ID NO:53. 26. The method of claim 25, wherein the patient is human. 27. The method of claim 26, wherein the patient's tumor is resistant to treatment with a chemotherapeutic agent. 28. The method of claim 26, wherein the patient's tumor has recurred following resection. 29. The method of claim 26, wherein the patient is concurrently receiving, or has received, at least one of chemotherapy, radiation therapy, and surgical therapy. 30. The method of claim 25, wherein the dendritic cells are allogeneic.
Graus, Yvo Maria Franciscus; Smit, Hobbe Friso; Osterhaus, Albertus Dominicus Marcellinus Erasmus; Hageman, Robert Johan Joseph, Chlorogenic acid and an analog thereof for immune system stimulation.
Altman John D. (San Carlos CA) McHeyzer-Williams Michael G. (Menlo Park CA) Davis Mark M. (Atherton CA), Compositions and methods for the detection, quantitation and purification of antigen-specific T cells.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
Hideaki Tahara JP; Michael T. Lotze ; Yasuhiko Nishioka JP, In situ injection of antigen-presenting cells with genetically enhanced cytokine expression.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Steinman Ralph M. ; Inaba Kayo,JPX ; Schuler Gerold,ATX, Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens.
Cohen Peter A. ; Czerniecki Brian J. ; Koski Gary K. ; Weng David E. ; Carter Charles ; Ojeifo John O. ; Schwartz Gretchen N., Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells.
Cohen Peter A. (Bethesda MD) Czerniecki Brian J. (Gaithersburg MD) Carter Charles (Gaithersburg MD) Fowler Daniel H. (Bethesda MD) Kim Hyun (Rochester MN), Method for isolating dendritic cells.
Edward L. Nelson ; Susan L Strobl, Methods and compositions for making dendritic cells from expanded populations of monocytes and for activating T cells.
Storkus Walter J. ; Lotze Michael T., Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients.
Boon Thierry,BEX ; Van Der Bruggen Pierre,BEX ; Van Den Eynde Benoit,BEX ; Van Pel Aline,BEX ; De Plaen Etienne,BEX ; Lurquin Christophe,BEX ; Chomez Patrick,BEX ; Traversari Catia,ITX, Tumor rejection antigen precursors, tumor rejection antigens and uses thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.